Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07519655 · ClinicalTrials.gov registry record · Phase 1
Phase 1 Study of PF-08046033 in Advanced Solid Tumors
A Phase 1 study, sponsored by Pfizer.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 250
- Enrollment target
NCT07519655: Recruiting Phase 1 study, sponsored by Pfizer.
NCT07519655 is a Phase 1 study that is actively recruiting participants, run by Pfizer. The registered enrollment target is 250 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (317% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07519655, a Phase 1 study, is actively recruiting participants, sponsored by Pfizer.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 250 participants
- Enrollment target
Study Summary
This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer. The study includes adult participants who have advanced cancers that cannot be removed by surgery or have spread to other parts of the body. These cancers include non-small cell lung cancer, esophageal squamous cell cancer, and melanoma. The study has two parts: In the first part, small groups of participants receive increasing doses of the study medicine. This helps researchers find a dose that is safe and suitable for further testing. Once a suitable dose is identified, the second part enrolls more participants with specific cancer types to better understand the safety of the medicine and whether it shows signs of helping control the cancer. Participants receive the study medicine through regular treatment cycles and are closely monitored for side effects and how their cancer responds. The information from this study will help researchers decide whether PF-08046033 should be studied further in later-stage clinical trials.
Primary Outcome
Type, incidence, severity (as graded by National Cancer Institute Common Terminology Criteria for Adverse Events \[NCI CTCAE\] v 5.0), seriousness, and relatedness of adverse events (AEs).
Interventions
- DRUG PF-08046033
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 250 participants |
| Start Date | 2026-04-08 |
| Est. Completion | 2029-07-14 |
| Phase | Phase 1 |
What NCT07519655 shows while recruiting
NCT07519655 is an interventional study that assigns participants to a tested intervention. The registered 250 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (317% higher).
The record links to 0 conditions, and to 1 intervention - of which PF-08046033 is the first listed.
NCT07519655 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07519655 about?
NCT07519655 is a clinical study titled "Phase 1 Study of PF-08046033 in Advanced Solid Tumors". This is an early-stage (Phase 1) clinical study testing a new study medicine called PF-08046033. The goal of the study is to understand how safe the medicine is, how well people tolerate it, how it behaves in the body, and whether it shows early signs of helping to treat cancer. The study includes ...
What is the current status of trial NCT07519655?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 250 participants. The study started on 2026-04-08. Estimated completion is 2029-07-14.
What interventions are being tested in trial NCT07519655?
The interventions under investigation include: PF-08046033 (DRUG).
Who is sponsoring clinical trial NCT07519655?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07519655's enrollment target sits among peer trials
250 173rd of 2000 higher than 1,816 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00483249 · 250 participants · NA
Endovascular Exclusion of Thoracoabdominal and/or Paravisceral Abdominal Aortic Aneurysm
- NCT00777712 · 250 participants
Mechanisms Underlying Impaired Diabetic Wound Healing
- NCT01451502 · 250 participants · NA
Infusion of Cell Populations From Unlicensed Umbilical Cord Blood Units
- NCT01771718 · 250 participants
Pilot Study on In-vivo Non-invasive Skin Imaging Using Multiphoton Microscopy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI